Aims: Despite their potential advantages, many of the pharmacological interventions available to treat substance misuse are controversial and their acceptability within the United Kingdom (and other countries) has only recently begun to be investigated.
Design: A questionnaire mailed to British National Health Service (NHS) alcohol and drug treatment services asked respondents to rate the acceptability and availability of 11 pharmacological interventions for substance misuse employed to relieve withdrawal, reduce the likelihood of relapse and opiate overdose and substitute pharmaceuticals for illicit drugs.
Participants: A sample of NHS substance misuse services (n = 265) listed in one or more directories of services in England, Wales and Scotland.
Findings: Substitute methadone for opiate addiction, substitute benzodiazepines for benzodiazepine-dependent patients, lofexidine for opiate detoxification, naltrexone for opiate relapse prevention and acamprosate for alcohol relapse prevention were widely acceptable and available interventions. Another subset of medications-buprenorphine for opiate detoxification, take-home naloxone for overdose prevention and substitute prescribing of levo-alpha-acetyl-methadol (LAAM), heroin and dexamphetamine-garnered less support, but the majority of participants rated even these therapies as acceptable. Ultra-rapid detoxification under sedation was the intervention rated as least acceptable to, and was one of the two least frequently available from, responding NHS services.
Conclusions: Differences among specific medications notwithstanding, a wide range of harm-reduction and abstinence-orientated interventions were acceptable to and available from NHS services. Acceptance and availability are probably limited by a combination of practical, economic, safety, efficacy and theoretical considerations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1360-0443.2002.00059.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Opioid use and abuse in adolescents and young adults; dealing with science, laws and ethics: Charming the COBRAS.
Dis Mon
January 2025
Department of Pediatric and Adolescent Medicine, Western Michigan University, Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
The subject of substance use disorders in the pediatric population remains a disturbing conundrum for clinicians, researchers and society in general. Many of our youth are at risk of being damaged and even killed by drug addictions that result from the collision of rapidly developing as well as vulnerable central nervous systems encountering the current global drug addiction crisis. A major motif of this chemical calamity is opioid use disorder in adolescents and young adults that was stimulated by the 19th century identification of such highly addictive drugs as morphine, heroin and a non-opiate, cocaine.
View Article and Find Full Text PDFExcipient lung disease with transient severe pulmonary hypertension in a healthcare professional injecting crushed oxycodone tablets.
BMJ Case Rep
January 2025
Department of Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia
Excipient lung disease (ELD) is a rare cause of pulmonary hypertension that occurs due to the intravenous injection of crushed tablets. We present the case of a healthcare professional in her late 30s who presented with a fever in the setting of a bacteraemia. During her hospital admission, she established a pattern of transient hypoxia and hypotension, with resolution without targeted management or clear cause identified.
View Article and Find Full Text PDFMailed smoking cessation support for Aboriginal and Torres Strait Islander people who smoke: protocol for a hybrid type 1 effectiveness - implementation trial.
BMJ Open
December 2024
The University of Newcastle College of Health Medicine and Wellbeing, Callaghan, New South Wales, Australia.
Introduction: Smoking is the leading preventable cause of death and the single most significant risk behaviour contributing to adverse health conditions among Aboriginal and Torres Strait Islander people. There is an urgent need for innovative approaches to support reductions in smoking prevalence. This study will assess the implementation and effectiveness of a mailed smoking cessation support programme that includes nicotine replacement therapy (NRT) () for Aboriginal and Torres Strait Islander people.
View Article and Find Full Text PDFOpioid toxicity deaths in Indigenous people who experienced incarceration in Ontario, Canada 2015-2020: a whole population retrospective cohort study.
Lancet Reg Health Am
January 2025
Department of Family Medicine, McMaster University, Canada.
Background: While Indigenous people are overrepresented in Canada's prisons and in the toxic drug supply crisis, we lack data on the harms related to opioids for Indigenous people with experiences of incarceration. We aimed to examine opioid toxicity deaths in Indigenous peoples who experienced incarceration and to compare opioid toxicity mortality rates with rates for people with no incarceration.
Methods: This retrospective cohort study linked correctional data for all people who were incarcerated in provincial correctional facilities and coronial data for all people who died from opioid toxicity in Ontario, Canada between 2015 and 2020.
Individual and Familial Risk and Promotive Factors for Substance Use Among Multiracial American Young Adults.
Subst Use Misuse
January 2025
McGill University, Montreal, Canada.
Background: Multiracial American adults have the highest rates of binge drinking and illicit drug use of all racial groups, yet little is known about the risk and promotive factors that contribute to their substance use.
Objectives: This study examines how individual factors (i.e.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!